Youssef Hassan, MD
Endocrinology, Diabetes & Metabolism · Wichita, KSNPI 1649207200
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,131, 7.0 times the $161 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in KS, where the typical reported total is $1,553.
Across 76 payments — averaging $22.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- BETA Bionics, Inc.$290
- Novo Nordisk$275
- Medtronic$269
- Amgen$131
- Lilly USA, LLC$120
- Teva Pharmaceuticals USA, Inc.$91
- plus $568 from 19 others
What the payments were for
- Food & beverage$1,65395%
- Education$915%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| BETA Bionics, Inc. | 11 | $290 |
| Novo Nordisk | 16 | $275 |
| Medtronic | 10 | $269 |
| Amgen(2 entities) | 5 | $131 |
| Lilly USA, LLC | 6 | $120 |
| Teva Pharmaceuticals USA, Inc. | 1 | $91 |
| AbbVie | 3 | $54 |
| Dexcom, Inc. | 2 | $52 |
| AstraZeneca(2 entities) | 2 | $50 |
| Corcept Therapeutics | 1 | $49 |
| Novartis | 3 | $49 |
| Astellas Pharma US Inc | 2 | $38 |
| IBSA Pharma Inc. | 2 | $33 |
| Rhythm Pharmaceuticals, Inc. | 1 | $27 |
| Nevro Corp. | 1 | $26 |
| Abbott | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Tandem Diabetes Care, Inc. | 1 | $19 |
| Averitas Pharma Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Merck | 1 | $13 |
How this compares
$1,744 in reported general payments places this provider in the 50th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
See all endocrinology, diabetes & metabolism providers in Kansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 114 | $133,828 |
| MounjaroTirzepatide | 54 | $88,499 |
| OzempicSemaglutide | 72 | $87,095 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $30,481 |
| TrulicityDulaglutide | 19 | $28,485 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $27,967 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $24,886 |
| JanuviaSitagliptin Phosphate | 19 | $22,077 |
| Humalog Kwikpen U-200Insulin Lispro | 13 | $17,603 |
| Novolog FlexpenInsulin Aspart | 24 | $4,988 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $4,043 |
| SynthroidLevothyroxine Sodium | 39 | $3,799 |
| Humalog Kwikpen U-100Insulin Lispro | 18 | $3,259 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 12 | $1,519 |
| Metformin Hcl ErMetformin Hcl | 79 | $1,146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $120 | $116,98473 claims |
| Novo NordiskOzempic | $275 | $87,09572 claims |
| MerckJanuvia | $13 | $22,07719 claims |
| AbbVieSynthroid | $54 | $3,79939 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
Other endocrinology, diabetes & metabolism in Wichita
- Dany ZayourWichita$744K
- Rami MortadaWichita$105K
- Georges ElhomsyWichita$14K
- Sahar HachemWichita$5K
- Ali JamalallailWichita$2K
- Syeda BatoolWichita$156
- Lillian HarstineWichita$12
- Andrew GreenShawnee Mission$322K
- Michael SokolOverland Park$227K
- Sajeev MenonOverland Park$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.